tradingkey.logo

Akero Therapeutics Inc <AKRO.OQ> expected to post a loss of 97 cents a share - Earnings Preview

ReutersMay 7, 2025 12:42 PM
  • Akero Therapeutics Inc AKRO.OQ AKRO.O is expected to show no change in quarterly revenue when it reports results on May 9 (estimated) for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Akero Therapeutics Inc is for a loss of 97 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Akero Therapeutics Inc is $77.50​, above​ its last closing price of $42.02. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-1.17

-1.15

-0.99

Beat

14.1

Sep. 30 2024

-0.91

-0.90

-1.05

Missed

-16.2

Jun. 30 2024

-0.86

-0.90

-0.81

Beat

9.9​

Mar. 31 2024

-0.96

-0.95

-0.90

Beat

5.5

​​Dec. 31 2023

-0.91

-0.86

-0.99

Missed

-14.9

Sep. 30 2023

-0.69

-0.68

-0.71

Missed

-4.2​

Jun. 30 2023

-0.62

-0.63

-0.60

Beat

4.5

Mar. 31 2023

-0.66

-0.67

-0.55

Beat

18.2

This summary was machine generated May 7 at 12:42 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI